| Autor: |
Payne CA; Hormones and Cancer Group, Cancer Genetics Laboratory, Kolling Institute of Medical Research, Reserve Road, St. Leonards, New South Wales, 2065 Australia., Maleki S, Messina M, O'Sullivan MG, Stone G, Hall NR, Parkinson JF, Wheeler HR, Cook RJ, Biggs MT, Little NS, Teo C, Robinson BG, McDonald KL |
| Jazyk: |
angličtina |
| Zdroj: |
Molecular cancer therapeutics [Mol Cancer Ther] 2008 Oct; Vol. 7 (10), pp. 3420-8. |
| DOI: |
10.1158/1535-7163.MCT-08-0629 |
| Abstrakt: |
Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D(2) (PGD(2)) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. In vitro, the addition of the main PGDS metabolite, PGD(2), to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGD(2) substitution also enhanced the efficacy of cyclo-oxygenase-2 inhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
